{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=temozolomide+200+mg%2Fm%5E2", "query": { "intervention": "temozolomide 200 mg/m^2" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 50, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=temozolomide+200+mg%2Fm%5E2&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-30T03:16:30.568Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00689221", "title": "Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Cilengitide", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 545, "start_date": "2008-09", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2014-11-04", "last_synced_at": "2026-09-30T03:16:30.568Z", "location_count": 1, "location_summary": "Rockland, Massachusetts", "locations": [ { "city": "Rockland", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00689221" }, { "nct_id": "NCT00068250", "title": "Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "temozolomide 100 mg/m^2", "type": "DRUG" }, { "name": "temozolomide 150 mg/m^2", "type": "DRUG" }, { "name": "temozolomide 200 mg/m^2", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "post-radiation therapy temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2003-07", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2018-02-07", "last_synced_at": "2026-09-30T03:16:30.568Z", "location_count": 26, "location_summary": "Jacksonville, Florida • Jacksonville Beach, Florida • Orange Park, Florida + 17 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville Beach", "state": "Florida" }, { "city": "Orange Park", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00068250" }, { "nct_id": "NCT01119508", "title": "Ipilimumab + Temozolomide in Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 64, "start_date": "2010-05", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2024-06-06", "last_synced_at": "2026-09-30T03:16:30.568Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01119508" }, { "nct_id": "NCT02781792", "title": "Temozolomide Chronotherapy for High Grade Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" }, { "name": "Functional Assessment of Cancer Therapy - Brain", "type": "OTHER" }, { "name": "ActTrust Condor Instrument Watch", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2016-08-11", "completion_date": "2024-07-18", "has_results": true, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-09-30T03:16:30.568Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02781792" }, { "nct_id": "NCT01740258", "title": "Bevacizumab Beyond Progression (BBP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Glioma", "Grade 4 Malignant Glioma", "Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2013-01", "completion_date": "2019-11-14", "has_results": true, "last_update_posted_date": "2021-01-26", "last_synced_at": "2026-09-30T03:16:30.568Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01740258" }, { "nct_id": "NCT03463265", "title": "Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma" ], "interventions": [ { "name": "nab-sirolimus", "type": "DRUG" }, { "name": "nab-sirolimus + temozolomide", "type": "DRUG" }, { "name": "nab-sirolimus + bevacizumab", "type": "DRUG" }, { "name": "nab-sirolimus + lomustine", "type": "DRUG" }, { "name": "nab-sirolimus + marizomib (MRZ)", "type": "DRUG" }, { "name": "nab-sirolimus + temozolomide + radiotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aadi Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2018-08-01", "completion_date": "2022-08-26", "has_results": true, "last_update_posted_date": "2023-11-07", "last_synced_at": "2026-09-30T03:16:30.568Z", "location_count": 3, "location_summary": "Fullerton, California • Newport Beach, California • Santa Monica, California", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03463265" }, { "nct_id": "NCT04757662", "title": "Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Grade III Astrocytoma", "Grade IV Astrocytoma", "Astrocytoma, Grade IV", "Astrocytoma, Grade III" ], "interventions": [ { "name": "Tadalafil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2021-05-14", "completion_date": "2023-06-07", "has_results": false, "last_update_posted_date": "2023-06-13", "last_synced_at": "2026-09-30T03:16:30.568Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04757662" }, { "nct_id": "NCT01236560", "title": "Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Brain Stem Glioma", "Cerebral Astrocytoma", "Childhood Cerebellar Anaplastic Astrocytoma", "Childhood Cerebral Anaplastic Astrocytoma", "Childhood Spinal Cord Neoplasm" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 101, "start_date": "2011-01-26", "completion_date": "2023-12-31", "has_results": true, "last_update_posted_date": "2024-02-20", "last_synced_at": "2026-09-30T03:16:30.568Z", "location_count": 124, "location_summary": "Birmingham, Alabama • Downey, California • Loma Linda, California + 98 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01236560" }, { "nct_id": "NCT05768919", "title": "Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Treatment Period 1", "type": "DRUG" }, { "name": "Treatment Period 2", "type": "DRUG" }, { "name": "Treatment Period 3", "type": "DRUG" }, { "name": "Treatment Period 4a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SignPath Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2023-03-03", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2024-11-29", "last_synced_at": "2026-09-30T03:16:30.568Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05768919" }, { "nct_id": "NCT00527657", "title": "Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Neoplasms", "Melanoma" ], "interventions": [ { "name": "Lomustine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2006-02-09", "completion_date": "2012-02-02", "has_results": false, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-09-30T03:16:30.568Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00527657" } ] }